ATRA

8.25

5.77% 0.45

Handel nachbörslich: 8.23 -0.02 -0.24%

Atara Biotherapeutics Inc (ATRA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ATRA? Forum Prognose

Schlusskurs vom Vortag:

$7.80

Offen:

$7.88

24-Stunden-Volumen:

31,148

Relative Volume:

0.54

Marktkapitalisierung:

$54.37M

Einnahmen:

$100.44M

Nettoeinkommen (Verlust:

$-133.16M

KGV:

-0.3203

EPS:

-25.76

Netto-Cashflow:

$-94.85M

1W Leistung:

+2.87%

1M Leistung:

+3.12%

6M Leistung:

-41.74%

1J Leistung:

+9.71%

1-Tages-Spanne:

$7.88

$8.3499

1-Wochen-Bereich:

$7.54

$8.3499

52-Wochen-Spanne:

$5.005

$18.70

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Firmenname

Atara Biotherapeutics Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (655)

Telefon

805-623-4211

Adresse

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Mitarbeiter

Twitter

@Atarabio

Nächster Verdiensttermin

2024-11-18

Neueste SEC-Einreichungen

ATRA's Discussions on Twitter

Vergleichen Sie ATRA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATRA Atara Biotherapeutics Inc	8.25	54.37M	100.44M	-133.16M	-94.85M	-25.76
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-11-09	Herabstufung	Evercore ISI	Outperform → In-line
2023-11-09	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-11-09	Herabstufung	Mizuho	Buy → Neutral
2022-07-20	Herabstufung	Citigroup	Neutral → Sell
2022-07-13	Herabstufung	JP Morgan	Overweight → Neutral
2022-07-13	Herabstufung	Stifel	Buy → Hold
2022-05-10	Herabstufung	Citigroup	Buy → Neutral
2021-05-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-12-09	Herabstufung	Citigroup	Buy → Neutral
2020-12-08	Bestätigt	H.C. Wainwright	Buy
2020-11-10	Bestätigt	H.C. Wainwright	Buy
2020-06-30	Eingeleitet	Evercore ISI	Outperform
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2020-04-23	Hochstufung	Citigroup	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Neutral
2019-09-27	Herabstufung	Goldman	Neutral → Sell
2019-09-16	Herabstufung	Jefferies	Buy → Hold
2019-06-04	Hochstufung	Citigroup	Sell → Neutral
2019-05-30	Eingeleitet	ROTH Capital	Buy
2019-05-23	Eingeleitet	Stifel	Buy
2019-01-23	Eingeleitet	Mizuho	Buy
2018-04-10	Eingeleitet	JP Morgan	Overweight
2018-03-16	Eingeleitet	Guggenheim	Neutral
2018-03-05	Bestätigt	Jefferies	Buy
2018-02-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Herabstufung	Citigroup	Neutral → Sell
2018-01-03	Hochstufung	Citigroup	Sell → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

Jun 16, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Jun 06, 2025

Jun 04, 2025

Northern Trust Corp Purchases New Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World

Jun 04, 2025

Jun 02, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Update - Defense World

Jun 02, 2025

Bank of America Corp DE Acquires 1,543 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World

Jun 02, 2025

May 29, 2025

Redmile Group, LLC's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus

May 29, 2025

May 28, 2025

Here's Why You Should Consider Buying Atara Biotherapeutics Stock - Barchart.com

May 28, 2025

Biotech Pioneer Pascal Touchon Joins CDR-Life Board: Former Atara CEO to Drive T Cell Platform Innovation - Stock Titan

May 28, 2025

May 27, 2025

(ATRA) Trading Advice - news.stocktradersdaily.com

May 27, 2025

May 22, 2025

Atara Biotherapeutics (NASDAQ:ATRA) & Turnstone Biologics (NASDAQ:TSBX) Financial Analysis - Defense World

May 22, 2025

May 20, 2025

Top Executives at Atara Biotherapeutics Make Significant Stock Sales! - TipRanks

May 20, 2025

Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView

May 20, 2025

Citadel Advisors LLC Has $3.56 Million Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World

May 20, 2025

May 19, 2025

FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal

May 19, 2025

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - BioSpace

May 19, 2025

May 18, 2025

Atara Biotherapeutics (ATRA) Expands Board Following $16 Million Offering | ATRA Stock News - GuruFocus

May 18, 2025

May 17, 2025

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors | ATRA Stock News - GuruFocus

May 17, 2025

Atara Biotherapeutics Reports Strong Q1 2025 Results - TipRanks

May 17, 2025

May 16, 2025

(ATRA) Investment Analysis and Advice - news.stocktradersdaily.com

May 16, 2025

Atara Biotherapeutics Announces $16M Stock Offering - TipRanks

May 16, 2025

Atara Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 16, 2025

Atara Biotherapeutics: Q1 Earnings Snapshot - CT Insider

May 16, 2025

Atara Biotherapeutics sets stock and warrant offering prices By Investing.com - Investing.com India

May 16, 2025

May 15, 2025

Atara Biotherapeutics prices $16M public offering - MSN

May 15, 2025

Atara Biotherapeutics (ATRA) Announces $16M Share Offering - GuruFocus

May 15, 2025

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress | ATRA Stock News - GuruFocus

May 15, 2025

Atara Biotherapeutics sets stock and warrant offering prices - Investing.com

May 15, 2025

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress - BioSpace

May 15, 2025

Atara Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2025

Atara Biotherapeutics Announces Pricing of $16 Million Offering - GuruFocus

May 15, 2025

Atara Biotherapeutics, Inc. SEC 10-Q Report - TradingView

May 15, 2025

Atara Biotherapeutics Announces Pricing of $16 Million Offering | ATRA Stock News - GuruFocus

May 15, 2025

May 12, 2025

Atara Biotherapeutics Announces Major Workforce Reduction - TipRanks

May 12, 2025

Atara Biotherapeutics To Reduce Workforce By 30% - marketscreener.com

May 12, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

May 12, 2025

May 10, 2025